NASDAQ$MMSI

Merit Medical Systems Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Merit Medical reported revenue increase and improved profitability in Q4 2023.

Merit Medical Systems, Inc. reported a 10.6% increase in revenue for Q4 2023, reaching $324.5 million. The company's non-GAAP operating margin improved to 18.2%, and it generated approximately $55 million in free cash flow. The company issued fiscal year 2024 guidance, reflecting confidence in continued strong execution, stable growth, improving profitability, and solid free cash flow generation.

  • Q4 2023 reported revenue increased by 10.6% year-over-year, reaching $324.5 million.
  • Constant currency revenue for Q4 2023 was up 10.3% year-over-year.
  • GAAP operating margin for Q4 2023 was 10.4%, consistent with Q4 2022, while non-GAAP operating margin improved to 18.2%.
  • GAAP EPS for Q4 2023 was $0.47, and non-GAAP EPS was $0.81.

Headline financials

Total Revenue

$323M

Previous: $293M+10.2%
EPS (adj)

$0.81

Previous: $0.79+2.5%
GAAP Operating Margin

10.4%

Previous: 10.4%+0.0%
Non-GAAP Operating Margin

18.2%

Previous: 17.8%+2.2%
Capital Expenditures

-$7.14M

Previous: $12.5M-157.2%
Net Income

$27.6M

Previous: $33.4M-17.3%
Operating Income

$33.6M

Previous: $30.4M+10.5%
Gross Profit

$151M

Previous: $135M+11.9%
R&D Expense

$21.6M

No prior period
Stock-Based Comp

$5.99M

Previous: $4.35M+37.6%

Revenue & EPS history

Merit Medical · Revenue · Quarterly

$323M

Q4 2023+10.2%vs Q4 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Merit Medical · $9.15M total across 1 segment · Q3 2023

  • Endoscopy
    $9.15M+11.2%

Forward guidance

For the year ending December 31, 2024, Merit expects net sales between $1.312 billion and $1.325 billion, cardiovascular segment sales between $1.272 billion and $1.285 billion, endoscopy segment sales between $39.7 million and $40.1 million, and non-GAAP earnings per share between $3.28 and $3.35.

Tailwinds

  • Net sales are expected to be between $1.312 billion and $1.325 billion, representing a 4% - 5% increase year-over-year.
  • Cardiovascular segment sales are projected to be between $1.272 billion and $1.285 billion, also a 4% - 5% increase.
  • Endoscopy segment sales are anticipated to be between $39.7 million and $40.1 million, an 8% - 9% increase.
  • Non-GAAP earnings per share are forecasted to be between $3.28 and $3.35, indicating a 9% - 11% increase.
  • Constant currency net sales are expected to increase by 4.8% - 5.9%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-0.1%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+1.8%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+16.5%

Q3 2014

Best reaction

-31.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.2%-6.8%-2.8%
Q4 2025-3.8%-7.2%-16.6%
Q3 2025+5.1%+4.9%+4.3%
Q1 2025-0.1%-0.2%+0.7%
Q4 2024-1.5%+1.0%+1.9%
Q3 2024+2.9%+3.3%+8.3%
Q2 2024+4.0%+5.0%+13.4%
Q1 2024+2.1%+5.2%+7.8%
Q4 2023-5.3%-4.9%-5.9%
Q3 2023+7.7%+7.3%+12.9%
Q2 2023-9.6%-8.3%-16.4%
Q1 2023+4.7%+5.1%+4.3%
Q4 2022+2.8%+1.3%+3.7%
Q3 2022+7.0%+14.6%+19.6%
Q2 2022+6.0%+10.6%+10.0%
Q1 2022-3.7%-4.7%-5.2%
Q4 2021+8.4%+9.3%+5.0%
Q3 2021-1.8%-5.1%-3.5%
Q2 2021+7.6%+3.9%+10.1%
Q1 2021-0.2%+1.4%-5.3%
Q4 2020-1.8%-0.4%+1.9%
Q3 2020+5.2%+1.3%+11.7%
Q2 2020+4.3%-1.9%+11.6%
Q1 2020+9.0%+6.5%+21.4%
Q4 2019+0.4%-9.5%-17.0%
Q3 2019-31.4%-15.5%-7.0%
Q2 2019-24.7%-26.2%-37.2%
Q1 2019-1.9%-4.7%-9.4%
Q4 2018-4.3%-2.1%+1.6%
Q3 2018-4.1%-5.3%-3.5%
Q2 2018+2.8%-3.1%+3.3%
Q1 2018+2.8%+7.5%+18.7%
Q4 2017-2.1%-5.1%-3.3%
Q3 2017-9.7%-11.0%+4.6%
Q2 2017+4.8%+5.5%+4.6%
Q1 2017+8.2%+8.2%+11.6%
Q4 2016+5.9%+4.8%+0.0%
Q3 2016-5.0%-5.0%+5.2%
Q2 2016+6.1%+6.7%+6.5%
Q1 2016+2.5%
Q4 2015-2.8%
Q3 2015-27.3%
Q2 2015+10.7%
Q1 2015+9.5%
Q4 2014+7.7%
Q3 2014+16.5%
Q2 2014-14.4%
Q1 2014-5.4%
Q4 2013+1.2%
Q3 2013+15.4%
Q2 2013+7.6%
Q1 2013-13.9%
Q4 2012-14.7%
Q3 2012-2.8%
Q2 2012-0.5%
Q1 2011-0.7%
Q4 2011-0.7%
Q1 2012+1.1%
Q1 2010-1.6%
Q4 2009-1.6%
Q3 2010-1.1%
Q3 2011-1.1%
Q2 2011+1.6%
Q2 2010+1.6%
Q4 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro